Key Takeaways BMY's Sotyktu met primary and multiple secondary endpoints in a phase III PsA study. Sotyktu showed superior efficacy over placebo at Week 16 and sustained responses through Week 52. RayzeBio inked a $1.35B licensing deal for Philochem's prostate cancer therapy, OncoACP3.Bristol Myers (BMY) announced that the late-stage study on Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA) met its primary endpoint.Sotyktu is an oral, selective tyrosine kinase 2 (TYK2) inhibitor w ...